AAAAAA
Results:
1-17
|
Results: 17
Authors:
Lasset, C
Bonadona, V
Mignotte, H
Bremond, A
Citation: C. Lasset et al., Tamoxifen and risk of endometrial cancer, LANCET, 357(9249), 2001, pp. 66-67
Authors:
Lasset, C
Bonadona, V
Citation: C. Lasset et V. Bonadona, Medical management of women with inherited predisposition to breast cancer: indications and procedures for mammographic screening, B CANCER, 88(7), 2001, pp. 677-686
Authors:
Frebourg, T
Ebel, A
Bonaiti-Pellie, C
Brugieres, L
Berthet, P
Bressac-De Paillerets, B
Chevrier, A
Chompret, A
Cohen-Haguenauer, O
Delattre, O
Feingold, J
Feunteun, J
Frappaz, D
Fricker, JP
Gesta, P
Jonveaux, P
Kalifa, C
Lasset, C
Leheup, B
Limacher, JM
Longy, M
Nogues, C
Oppenheim, D
Sommelet, D
Soubrier, F
Stoll, C
Stoppa-Lyonnet, D
Tristant, H
Citation: T. Frebourg et al., Li-Fraumeni syndrome: update, new data and guidelines for clinical management, B CANCER, 88(6), 2001, pp. 581-587
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21
Authors:
McKay, JD
Lesueur, F
Jonard, L
Pastore, A
Williamson, J
Hoffman, L
Burgess, J
Duffield, A
Papotti, M
Stark, M
Sobol, H
Maes, B
Murat, A
Kaariainen, H
Bertholon-Gregoire, M
Zini, M
Rossing, MA
Toubert, ME
Bonichon, F
Cavarec, M
Bernard, AM
Boneu, A
Leprat, F
Haas, O
Lasset, C
Schlumberger, M
Canzian, F
Goldgar, DE
Romeo, G
Citation: Jd. Mckay et al., Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21, AM J HU GEN, 69(2), 2001, pp. 440-446
Authors:
Lakhani, SR
Gusterson, BA
Jacquemier, J
Sloane, JP
Anderson, TJ
van de Vijver, MJ
Venter, D
Freeman, A
Antoniou, A
McGuffog, L
Smyth, E
Steel, CM
Haites, N
Scott, RJ
Goldgar, D
Neuhausen, S
Daly, PA
Ormiston, W
McManus, R
Scherneck, S
Ponder, BAJ
Futreal, PA
Peto, J
Stoppa-Lyonnet, D
Bignon, YJ
Struewing, JP
Bishop, DT
Klijn, JGM
Devilee, P
Cornelisse, CJ
Lasset, C
Lenoir, G
Barkardottir, RB
Egilsson, V
Hamann, U
Chang-Claude, J
Sobol, H
Weber, B
Easton, DF
Stratton, MR
Citation: Sr. Lakhani et al., The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2, CLIN CANC R, 6(3), 2000, pp. 782-789
Authors:
Frappaz, D
Michon, J
Coze, C
Berger, C
Plouvier, E
Lasset, C
Bernard, JL
Stephan, JL
Bouffet, E
Buclon, M
Combaret, V
Fourquet, A
Philip, T
Zucker, JM
Citation: D. Frappaz et al., LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis, J CL ONCOL, 18(3), 2000, pp. 468-476
Authors:
Voog, E
Merrouche, Y
Trillet-Lenoir, V
Lasset, C
Peaud, PY
Rebattu, P
Negrier, S
Citation: E. Voog et al., Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary, AM J CL ONC, 23(6), 2000, pp. 614-616
Authors:
Julian-Reynier, C
Eisinger, F
Chabal, F
Lasset, C
Nogues, C
Stoppa-Lyonnet, D
Vennin, P
Sobol, H
Citation: C. Julian-reynier et al., Disclosure to the family of breast/ovarian cancer genetic test results: Patient's willingness and associated factors, AM J MED G, 94(1), 2000, pp. 13-18
Authors:
Eisinger, F
Julian-Reynier, C
Stoppa-Lyonnet, D
Lasset, C
Nogues, C
Citation: F. Eisinger et al., Acceptability of prophylactic mastectomy in cancer-prone women, J AM MED A, 283(2), 2000, pp. 202-203
Authors:
Negrier, S
Ollivier, L
Di Stefano-Louineau, D
Escudier, B
Savary, J
Lasset, C
Thiesse, P
Citation: S. Negrier et al., Response rate accuracy in oncology - Analysis of causes for variation, B CANCER, 87(12), 2000, pp. 927-934
Authors:
Cottin, V
Arpin, D
Lasset, C
Cordier, JF
Brune, J
Chauvin, F
Trillet-Lenoir, V
Citation: V. Cottin et al., Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole, ANN ONCOL, 10(7), 1999, pp. 809-815
Authors:
Escudier, B
Chevreau, C
Lasset, C
Douillard, JY
Ravaud, A
Fabbro, M
Caty, A
Rossi, JF
Viens, P
Bergerat, JP
Savary, J
Negrier, S
Citation: B. Escudier et al., Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?, J CL ONCOL, 17(7), 1999, pp. 2039-2043
Authors:
Wang, Q
Lasset, C
Desseigne, F
Saurin, JC
Maugard, C
Navarro, C
Ruano, E
Descos, L
Trillet-Lenoir, V
Bosset, JF
Puisieux, A
Citation: Q. Wang et al., Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer, HUM GENET, 105(1-2), 1999, pp. 79-85
Authors:
Sobol, H
Bignon, YJ
Bonaiti, C
Cuisenier, J
Lasset, C
Lortholary, A
Nogues, C
Stoppa-Lyonnet, D
Eisinger, F
Citation: H. Sobol et al., Four years analysis of cancer genetic clinics activity in France from 1994to 1997: A survey on 801 patients, DIS MARKER, 15(1-3), 1999, pp. 15-29
Authors:
Wang, Q
Lasset, C
Desseigne, F
Frappaz, D
Bergeron, C
Navarro, C
Ruano, E
Puisieux, A
Citation: Q. Wang et al., Neurofibromatosis and early onset of cancers in hMLH1-deficient children, CANCER RES, 59(2), 1999, pp. 294-297
Authors:
Mignotte, H
Perol, D
Fontaniere, B
Nachury, LP
Blanc-Jouvand, A
Fouillat, V
Chauvin, F
Lasset, C
Citation: H. Mignotte et al., Cervical cancer screening for high risk women: is it possible? Results of a cervical cancer screening program in three suburban districts of Lyon, B CANCER, 86(6), 1999, pp. 573-579
Authors:
Serova-Sinilnikova, O
Egan, K
Boutrand, L
Stoppa-Lyonnet, D
Desjardins, L
Levy, C
Bignon, YJ
Lasset, C
Haguenauer, O
Goldgar, D
Lenoir, GM
Citation: O. Serova-sinilnikova et al., Implication of germline BRCA2 gene mutations for the occurrence of ocular melanoma and pancreatic cancer, EUROCANCER 98, 1998, pp. 113-114
Risultati:
1-17
|